American Heart Association (AHA)

The American Heart Association (AHA) funds cardiovascular medical research, educates consumers on healthy living and fosters appropriate cardiac care in an effort to reduce disability and deaths caused by cardiovascular disease and stroke. The AHA also is a key resource for the latest cardiology science through its journals and annual meeting.

New AI program delivers rapid, accurate echo video assessments
The new technology shows early potential to make a significant impact on imaging workflows and patient care.
Genetic predisposition to depression increases CVD risk in women, but not men
The heightened risks were even seen in women who were never diagnosed with a psychiatric disorder. It remains unclear why the same trend was not seen in men.
ATTR-CM drug acoramidis, now approved by the FDA, linked to positive long-term data
Cardiovascular Business spoke with cardiologist Daniel Judge, MD, about the long-term benefits of acoramidis, a new drug therapy that just received FDA approval to treat transthyretin amyloid cardiomyopathy.
Martha Gulati highlights 'exciting' progress in preventive cardiology
Martha Gulati, MD, spoke to Cardiovascular Business at AHA Scientific Sessions 2024 about key developments in obesity treatment and CVD prevention.
LAAC with Watchman FLX reduces bleeding risks after AFib ablation
The new data, presented during AHA Scientific Sessions 2024, suggest LAAC with Boston Scientific's Watchman FLX could be a safe, effective alternative to OAC for limiting post-ablation strokes.

Atrial Fibrillation and its location in the atrium detected using the Vektor arrhythmia detection software. COVID infection can cause the development of AFib, AF, in patients as a long-COVID symptom.

VIDEO: The link between COVID-19 and atrial fibrillation

Peter Libby, MD, a cardiovascular medicine specialist with Brigham and Women’s Hospital, discussed the cases of AFib being seen in long-COVID patients.

January 30, 2023

Nemours Children's Hospital pediatric cardiologists explain lessons learned about cardiac involvement and long-term issues from multisystem inflammatory syndrome in children (MIS-C), a rare but serious disease caused by exposure to the COVID-19 virus. #MIS-C #COVID #coronavirus #SARSCoV2

VIDEO: Cardiologists share the latest details on COVID-related MIS-C

In this new video, pediatric cardiologists discuss some of the long-term issues associated with multisystem inflammatory syndrome in children (MIS-C), a rare disease linked to COVID-19.

January 26, 2023

COVID-19 caused CVD deaths in the U.S. to spike, new research confirms

Researchers explored updated data from the AHA, noting that the number of CVD-related deaths increased from more than 874,000 in 2019 to more than 928,000 in 2020.

January 25, 2023

Why more pulmonary embolism patients should be considered for surgery

The topic was explored at length in a new scientific statement presented at the 59th Annual Meeting of the Society of Thoracic Surgeons.

January 23, 2023

AHA: ‘Mini strokes’ need emergency assessment, may require hospitalization

Even if symptoms disappear quickly, a transient ischemic attack can be a major short-term risk indicator.

January 20, 2023

Intermittent fasting not associated with long-term weight loss, according to new 6-year analysis

Reducing total calorie intake and minimizing large meals, on the other hand, were both linked to improved weight loss. The study followed participants for an average of 6.3 years.

January 18, 2023

EHR intervention targets acute kidney injuries after PCI

Contrast-associated acute kidney injury is a significant problem in cardiology, especially among patients undergoing percutaneous coronary intervention. Can EHR-generated alerts make an impact?

January 18, 2023

Peter Libby, MD, a cardiovascular medicine specialist, Brigham and Women’s Hospital, and Mallinckrodt Professor of Medicine, Harvard Medical School, explains the take aways from the PROMINENT trial using pemafibrate to lower cardiovascular risks. The trial, presented at the American Heart Association (AHA) 2022 meeting, did not show reduction in the incidence of cardiovascular events among those who received pemafibrate than among those who received placebo. #AHA #AHA22

VIDEO: Pemafibrate does not lower cardiovascular risks in the PROMINENT trial

Peter Libby, MD, a cardiovascular medicine specialist with Brigham and Women’s Hospital and Harvard Medical School, explained some key takeaways from the PROMINENT trial.

January 17, 2023

American Heart Association (AHA)

New AI program delivers rapid, accurate echo video assessments

Genetic predisposition to depression increases CVD risk in women, but not men

ATTR-CM drug acoramidis, now approved by the FDA, linked to positive long-term data

Martha Gulati highlights 'exciting' progress in preventive cardiology

LAAC with Watchman FLX reduces bleeding risks after AFib ablation